Method for preparing (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4h-isoxazol-3-yl]-2-methyl-benzoic acid

A new synthetic route for producing enantiopure (S)-fluralaner using a simple solvent system and basic compounds in organic solvents, followed by acidic treatment, addresses inefficiencies in existing methods, achieving high enantiomeric purity and yield without chromatographic purification.

JP2024167399AInactive Publication Date: 2024-12-03INTERVET INT BV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024153127
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-12-21
Filing Date
2024-09-05
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing methods for producing enantiopure (S)-fluralaner, an important intermediate in the synthesis of the synthetic insecticide fluralaner, are inefficient and require complex solvent systems or chromatographic purification, leading to low yields and enantiomeric purity.

Method used

A new synthetic route involving the use of a simple solvent system with specific organic solvents and basic or alkaline compounds to precipitate (S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, followed by treatment with an acidic aqueous solution and extraction, eliminating the need for chromatographic purification.

Benefits of technology

The method achieves high enantiomeric excess and yield of (S)-fluralaner with a simplified process, avoiding complex equipment and chromatographic steps.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167399000001
    Figure 2024167399000001
  • Figure 2024167399000002
    Figure 2024167399000002
  • Figure 2024167399000003
    Figure 2024167399000003
Patent Text Reader

Abstract

To provide a method for preparing a key intermediate for the synthesis of (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-2-methyl-benzamide.SOLUTION: The present invention relates to a novel method for preparing (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, which is a key intermediate.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention preferably comprises (5S)-4-[5-(3,5-dichlorophenyl)-5-(trichlorophenyl)- Trifluoromethyl)-4H-isoxazol-3-yl]-N-[2-oxo-2-( Synthesis of 2,2,2-trifluoroethylamino)ethyl]-2-methyl-benzamide (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluorophenyl)phenyl]-2,4-dichlorophenyl A new preparation of 4H-isoxazol-3-yl-2-methylbenzoic acid. This relates to the manufacturing method. [Background technology]

[0002] (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl) -4H-isoxazol-3-yl]-N-[2-oxo-2-(2,2,2-triphenylphosphine] Fluralaner is a compound which is used to treat (A) is a synthetic insecticide represented by the following formula (A): [ka]

[0003] Fluralaner is an orally administered systemically active ingredient. To γ-aminobutyric acid (GABA) and / or glutamate receptors in the arthropod nervous system It has been reported that it competitively inhibits chloride channels through the binding of Although IL-1 does not show similar binding in the mammalian nervous system, e.g. Suitable for treating fleas, ticks and mites in dogs and cats.

[0004] Fluralaner is a racemate. The (S)-enantiomer is the active ingredient in It has been reported that the eutomer contributes substantially to the Compared with fluralaner, enantiopure or enantiomerically enriched (S)-fluralaner It is believed to be advantageous to use

[0005] (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl) -4H-Isoxazol-3-yl]-2-methyl-benzoic acid (IOBA) is It is an important intermediate in the LaNel synthesis, and the compound is represented by the following formula (1): . [ka]

[0006] Enantiopure or enantiomerically enriched (S)-fluralaner is advantageous as an active ingredient. Therefore, enantiopure or enantiomerically enriched (5S)-4-[5- (3,5-Dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazole It is believed that the isolation of S-IOBA is desirable. (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)

[0033] 4H-isoxazol-3-yl]-2-methyl-benzoic acid can be synthesized by the following formula (1a): This is expressed as: [ka]

[0007] WO2014 / 090918A1 describes the separation of similar compounds into enantiomers using a method called chiral separation. This can be done by parallel column chromatography or by diastereomeric recrystallization. In detail, the document states that it is possible to obtain a similar compound, racemic mixture 3. -Methyl-5-[(5RS)-5-(3,4,5-trichlorophenyl)-5-(trifluorophenyl) (fluoromethyl)-4H-isoxazol-3-yl]thiophene-2-carboxylic acid (I OTA) in a ternary mixture of water, acetonitrile and 2-butanol. (S)-isoxazoline A precipitate of thiophene carboxylate was obtained, which after washing had a chiral purity of >95%. It is stated that the purity can be increased to more than 98% by a further recrystallization step. However, this method uses a ternary mixture of solvents for crystallization. In 14 / 090918A1, the "by-products" remaining in the ternary mixture ( If you want to racemize R-isoxazolinethiophene carboxylic acid, use this ternary solvent mixture. In addition, racemic IOBA needs to be converted to a different solvent. Treatment with (phenyl)ethylamine did not result in precipitation of (R)-IOBA or (S)-IOBA. It was found that this did not occur at all.

[0008] JP05679102 describes a method for preparing a racemic isoxazoline benzoic acid derivative and its enantiomeric derivative. There are methods by which the thiomers can be separated, using organic solvents or mixtures thereof. The reaction is carried out in a 5-methyl-2-phenyl-1,2-diphenyl-2-propanediol (5RS)-1,2-di ... )-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-iso [3-isoxazolyl]-2-methyl-benzoic acid and optically active α-phenylethyl The amine was reacted in a mixture of toluene and ethyl acetate or in ethyl acetate alone to give a precipitate, It is (5S)-4-[5-(3,5-dichlorophenyl)-5-(trichlorophenyl)- Fluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid The enantiomeric salts and (S)-α-phenylethylamine were [Prior art documents] [Patent documents]

[0009] [Patent Document 1] WO2014 / 090918A1 [Patent Document 2] JP05679102 Summary of the Invention [Problem to be solved by the invention]

[0010] However, there is still a need for new synthetic routes, preferably in a simple and efficient manner. (5S)-4-[5-(3,5-dichlorophenyl)-5-(trichlorophenyl)-2-(2,4-dichlorophenyl)-1,2,3-tetrachlorophenyl]-2,4-dichlorophenyl] ... Preparation of (trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid A method of manufacture is needed.

[0011] It is therefore an object of the present invention to overcome one or more of the drawbacks of the above-mentioned methods. The aim of this study was to develop a novel (5S)-4-[5-(3,5-dichlorophenyl)phenyl]phenyl ether with high enantiomeric excess. phenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl Another object of the present invention is to provide a method for the preparation of ethyl-benzoic acid, particularly for use in large-scale processes. When the reaction is carried out in a manner that is convenient for the synthesis of (5S)-4-[5-(3,5-dichlorophenyl)- 5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoate It is an object of the present invention to provide a method for producing aromatic acids using a simple solvent system. (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl) The present invention provides a method for producing 1,4-dihydro-4H-isoxazol-3-yl-2-methyl-benzoic acid. It is a further object of the present invention to provide a method for the precipitation of (S)-IOBA using the same solvent system. , (5S)-4-[5-(3,5- Dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl The present invention provides a method for producing 2-methyl-benzoic acid. [Means for solving the problem]

[0012] The present invention unexpectedly provides a new synthetic route for the preparation of compounds according to formula (1a). By doing so, at least one of the above objects has been achieved.

[0013] The subject of the present invention is therefore the (5S)-4-[5-(3,5-dioxo)phenylene according to formula (1a): 5-(trifluoromethyl)-4H-isoxazol-3-yl]- 2-Methyl-benzoic acid: [ka]

[0014] (5RS)-4-[5-(3,5-dichlorophenyl)-5-( Trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid: [ka]

[0015] A method for producing the same comprising the steps of: (i) (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoro methyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid of formula (2A), Compound (2B) or (2C): [ka]

[0016] [wherein R is an alkyl group having 1 or 2 carbon atoms], [ka]

[0017] [In the formula, X is Cl or Br.] and polarity E T (30) The reaction is carried out in an organic solvent having a molecular weight of 130 to 175 kJ / mol. forming a filtrate and a supernatant solution; (ii) separating the precipitate from step (i) from the supernatant solution; (iii) treating the precipitate from step (ii) with an aqueous acidic solution; and (iv) (S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl) 4H-isoxazol-3-yl]-2-methyl-benzoic acid in step (iii from the aqueous acid solution of With the proviso that when R is methyl, the solvent in step (i) is not ethyl acetate be.

[0018] Unexpectedly, the process of the present invention provides advantageous yields of resulting compounds having high enantiomeric excess. Moreover, the method can be performed without using any complicated equipment. This can be done to avoid the need for chromatographic purification. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] The present invention relates to a compound according to formula (1a) comprising steps (i), (ii), (iii) and (iv). The present invention relates to a method for producing a compound according to the present invention. In this embodiment, steps (i), (ii), (iii) and (iv) are carried out sequentially. It can be done.

[0020] The compound according to formula (1a) is a compound according to formula (1), (5RS)-4-[5-(3,5- Dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl ]-2-methyl-benzoic acid, and the compound according to formula (1) is e.g. For example, it can be produced according to the method described in Synthesis Example 3 of US2007 / 0066617. Cut.

[0021] In step (i) of the process according to the invention and / or any embodiment thereof, (5R S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H- [Isoxazol-3-yl]-2-methyl-benzoic acid was reacted with the polar T (30) 130~1 In an organic solvent having a molecular weight of 75 kJ / mol, the compound of formula (2A), (2B) or (2C) is reacted with The reaction is allowed to proceed to form a precipitate and a supernatant solution.

[0022] In formula (2A), the residue R is an alkyl group having 1 or 2 carbon atoms. .

[0023] In a preferred embodiment of the present invention and / or embodiments thereof, the residue R is a one carbon atom. The residue R is a methyl group. The potash compound is (S)-1-phenylethylamine.

[0024] In another preferred embodiment of the invention and / or embodiments thereof, the residue R has two carbon atoms. The residue R is an alkyl group having a hydrogen atom. That is, the residue R is an ethyl group. The alkaline compound is (S)-1-phenylpropylamine.

[0025] The compound according to formula (2B) is (R)-1-phenyl-2-methyl-propylamine. do.

[0026] In formula (2C), the residue X is Cl or Br.

[0027] In a preferred embodiment and / or embodiment thereof of the present invention, the residue in formula (2C) The group X is Cl and the corresponding basic or alkaline compound is (R)-1-(4-chloro (phenyl)-ethylamine.

[0028] In a more preferred embodiment, the residue X in formula (2C) is Br and the corresponding salt The basic or alkaline compound is (R)-1-(4-bromophenyl)-ethylamine. be.

[0029] In a preferred embodiment of the present invention and / or embodiments thereof, the compound of formula (2A), (2B) or the compound (2C) is (S)-1-phenyl-propylamine, (R)-1-phenyl R-2-methyl-propylamine, (R)-1-(4-chlorophenyl)-ethylamine and (R)-1-(4-bromophenyl)-ethylamine.

[0030] In a preferred embodiment of the present invention and / or in accordance with embodiments thereof, (5RS)-4-[5 -(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol- In step (i), a 2-methyl-3-yl-benzoic acid of formula (2A), (2B) or ( 2C) with the compound of formula (I) at a ratio of 1:0.4 to 1:5, preferably at a ratio of 1:0.5 to 1:3, more preferably The reaction is carried out in a molar ratio of 1:0.6 to 1:2, particularly 1:0.7 to 1:1.

[0031] Organic solvents are liquid compounds that dissolve substances, preferably completely, to form a solution. Examples of organic solvents are known in the art. The organic solvent may be, for example, a solvent having a low boiling point, low boiling point solvents), their acidity / baseness (acidic or alkaline solvents) and / or their They can be categorized by their polarity (polar and non-polar solvents).

[0032] E T (30) values ​​are taken as an indication of the polarity of different solvents (e.g., Jose P Ceron-Carrasco et al.:″Solvent polarit y scales: determination of new E T (30) v lues for 84 organic solvents″, Research Article; Journal of Physical Organic Che (See Mistry, 2014, 27, pages 512-518.) T (30) value is the negative solvatochromic dye also known as betaine 30 or Reichardt dye. 2,6-diphenyl-4-(2,4,6-triphenylpyridine-1-ium-1 Betaine 30 is obtained by the compound represented by the following formula (B): This is expressed as: [ka]

[0033] More specifically, E T (30) The values ​​are for the longest wavelength VIS / NIR adsorption bands in the corresponding solvents. , measured using betaine 30. High E T (30) values ​​are considered to correspond to highly polar solvents. On the other hand, low E T (30) values ​​indicate low polarity solvents. Thus, E T (30) Value The higher the E, the more polar the solvent, and vice versa. T (30) The value is the molar electronic excitation energy is also defined as, and is calculated as follows:

number

[0034] In the formula, λ max is the beta value in the corresponding solvent when measured at 25°C and 101 kPa. The superwavelength adsorption bands in the visible / near IR region of 30 are shown.

[0035] In step (i) of the process, the organic solvent is E T (30) Value: 130-175 kJ / mol has.

[0036] E T (30) Examples of solvents with values ​​between 130 and 175 kJ / mol are aliphatic, cycloaliphatic Aliphatic or aromatic ethers, such as ethylene glycol dimethyl ether, triethylene glycol Dimethyl ether, 1,2-dimethoxyethane, di-n-butyl ether, di- tert-Butyl ether, diisopropyl ether, n-butyl methyl ether, tert-butyl ether, cyclopentyl methyl ether, dioxane, tetrahydrofuran Dropyran, 2,2,5,5-tetramethyltetrahydropyran, tetrahydrofuran, Tetrahydro-2-methylfuran, 2,2,5,5-tetramethyltetrahydrofuran, Benzyl methyl ether, dibenzyl ether, anisole, 3-methylanisole and Phenetole; arenes and pyridines, such as benzene, toluene, m-xylene and Mesitylene; haloarenes, such as chlorobenzene, 1,3-dichlorobenzene, bromo Benzene and 1,3-dibromobenzene and pyridine; aliphatic esters, e.g. methyl formate ethyl, methyl acetate, methyl propanoate, methyl butanoate, methyl hexanoate, ethyl formate , ethyl acetate, ethyl propanoate, ethyl benzoate and butyl acetate; aliphatic, cycloaliphatic Aliphatic or aromatic amines, for example diethylamine, triethylamine, diisopropylamine, haloalkanes, such as trichloromethane, tetrachloromethane; Methane, 1,1-dichloroethane, 1,2-dichloroethane and 1,1,2,2-tetrachloroethane Chloroethane and mixtures thereof.

[0037] In a preferred embodiment of the present invention and / or embodiments thereof, the organic solvent is E T (30 ) value is 132 to 175 kJ / mol, preferably 134 to 174 kJ / mol, more preferably Generally, 135 to 170 kJ / mol, particularly 140 to 165, and more particularly 134 to 160 has kJ / mol.

[0038] In a preferred embodiment of the present invention and / or embodiments thereof, the organic solvent is aliphatic or Cycloaliphatic ethers, e.g., ethylene glycol dimethyl ether, triethylene glycol Dimethyl ether, 1,2-dimethoxyethane, di-n-butyl ether, di- tert-Butyl ether, diisopropyl ether, n-butyl methyl ether, tert-butyl ether, cyclopentyl methyl ether, dioxane, tetrahydrofuran tetrahydrofuran, tetrahydro-2-methylfuran; allenes, e.g. benzene, toluene, m -Xylene, mesitylene, haloalkenes, e.g. chlorobenzene, bromobenzene; fats Aromatic esters, such as methyl acetate, methyl propanoate, methyl butanoate, ethyl acetate, Ethyl acetate, ethyl benzoate, butyl acetate; aliphatic amines, such as diethylamine, triethylamine, diisopropylamine; haloalkanes, e.g. trichloromethane, tetrachloromethane Dichloromethane, 1,1-dichloroethane and 1,2-dichloroethane and mixtures thereof It is.

[0039] In a preferred embodiment of the present invention and / or embodiments thereof, the organic solvent is methyl t ert-butyl ether, cyclopentyl methyl ether, tetrahydrofuran, diox San, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate , triethylamine, trichloromethane, 1,2-dichloroethane and mixtures thereof The compound is selected from the group consisting of:

[0040] In a preferred embodiment of the present invention and / or embodiments thereof, the organic solvent is methyl t In a preferred embodiment of the present invention and / or its embodiments, In the preferred embodiment of the present invention, the organic solvent is cyclopentyl methyl ether. And / or in an embodiment thereof, the organic solvent is tetrahydrofuran. In a preferred embodiment and / or embodiments thereof, the organic solvent is dioxane. In a preferred embodiment of the present invention and / or embodiments thereof, the organic solvent is chlorobenzene In a preferred embodiment of the present invention and / or embodiments thereof, the organic solvent is In a preferred embodiment of the present invention and / or in accordance with an embodiment thereof, The solvent is m-xylene. In a preferred embodiment of the present invention and / or its embodiments In the present invention, the organic solvent is mesitylene. In one embodiment, the organic solvent is ethyl acetate. In this embodiment, the organic solvent is butyl acetate. In one embodiment thereof, the organic solvent is triethylamine. In certain and / or embodiments thereof, the organic solvent is trichloromethane. In a preferred embodiment of the present invention and / or embodiments thereof, the organic solvent is 1,2-di It is chloroethane.

[0041] In a preferred embodiment of the present invention and / or embodiments thereof, the organic solvent is methyl t ert-butyl ether, cyclopentyl methyl ether, tetrahydrofuran, diox San, chlorobenzene, toluene, m-xylene, mesitylene, butyl acetate, triethyl From the group consisting of amines, trichloromethane, 1,2-dichloroethane and mixtures thereof Be selected.

[0042] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2A), the residue R is methyl and the organic solvent is methyl tert-butyl ether, cyclohexane. Pentyl methyl ether, tetrahydrofuran, dioxane, chlorobenzene, toluene , m-xylene, mesitylene, butyl acetate, triethylamine, trichloromethane, 1, 2-dichloroethane, and mixtures thereof.

[0043] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2A), the residue R is methyl and the organic solvent is methyl tert-butyl ether, cyclohexane. Pentyl methyl ether, dioxane, chlorobenzene, toluene, m-xylene, methionine Ethylene, butyl acetate, triethylamine, trichloromethane, 1,2-dichloroethane and and mixtures thereof.

[0044] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2A), the residue R is methyl, and the organic solvent is dioxane, chlorobenzene, toluene, Butyl acetate, triethylamine, trichloromethane, 1,2-dichloroethane and these and mixtures thereof.

[0045] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) (2A) residue R is methyl and the organic solvent is methyl tert-butyl ether; or in step (i) the residue R of formula (2A) is methyl and the organic solvent is cyclopentyl or the residue R of formula (2A) in step (i) is methyl; the organic solvent is tetrahydrofuran, or the residue R of formula (2A) is methyl, is dioxane, or the residue R of formula (2A) is methyl and the organic solvent is chlorobenzene. or the residue R of formula (2A) is methyl and the organic solvent is toluene, or The residue R of formula (2A) is methyl and the organic solvent is m-xylene, or The group R is methyl and the organic solvent is mesitylene, or the residue R of formula (2A) is methyl. and the organic solvent is butyl acetate, or the residue R of formula (2A) is methyl and the organic solvent is is triethylamine, or the residue R of formula (2A) is methyl and the organic solvent is trichloroethylene. or the residue R in formula (2A) is methyl and the organic solvent is 1,2-dichloromethane. It's Loetan.

[0046] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2A), the residue R is ethyl and the organic solvent is methyl tert-butyl ether, cyclohexane. Pentyl methyl ether, tetrahydrofuran, dioxane, chlorobenzene, toluene , m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, trichloro The gas is selected from the group consisting of methane, 1,2-dichloroethane, and mixtures thereof.

[0047] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2A), the residue R is ethyl and the organic solvent is methyl tert-butyl ether, cyclohexane. Pentyl methyl ether, dioxane, chlorobenzene, toluene, m-xylene, methionine Ethylene, ethyl acetate, butyl acetate, triethylamine, trichloromethane, 1,2-dichloromethane The inorganic filler is selected from the group consisting of chloroethane and mixtures thereof.

[0048] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2A), the residue R is ethyl and the organic solvent is methyl tert-butyl ether, cyclohexane. Pentyl methyl ether, dioxane, chlorobenzene, toluene, m-xylene, methionine Ethylene, ethyl acetate, butyl acetate, triethylamine, 1,2-dichloroethane and and mixtures thereof.

[0049] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2A), the residue R is ethyl and the organic solvent is methyl tert-butyl ether, cyclohexane. Pentyl methyl ether, chlorobenzene, m-xylene, mesitylene, ethyl acetate, vinegar From the group consisting of butyl acetate, triethylamine, 1,2-dichloroethane and mixtures thereof are selected.

[0050] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) (2A) residue R is ethyl and the organic solvent is methyl tert-butyl ether; Or in step (i), the residue R of formula (2A) is ethyl and the organic solvent is cyclopentyl or the residue R of formula (2A) in step (i) is ethyl, the organic solvent is tetrahydrofuran, or the residue R of formula (2A) is ethyl, is dioxane, or the residue R in formula (2A) is ethyl and the organic solvent is chlorobenzene. or the residue R of formula (2A) is ethyl and the organic solvent is toluene, or The residue R of formula (2A) is ethyl and the organic solvent is m-xylene, or The group R is ethyl and the organic solvent is mesitylene, or the residue R in formula (2A) is ethyl. and the organic solvent is ethyl acetate, or the residue R of formula (2A) is ethyl and the organic solvent is butyl acetate, or the residue R in formula (2A) is ethyl and the organic solvent is triethyl acetate. or the residue R in formula (2A) is ethyl and the organic solvent is trichloromethane. or the residue R of formula (2A) is ethyl and the organic solvent is 1,2-dichloroethane. .

[0051] In a preferred embodiment of the present invention and / or embodiments thereof, The aryl base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) The organic solvent is tetrahydrofuran, or the chiral base is (R)-1-phenyl-2-methyl and the organic solvent is dioxane, or the chiral base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) and the organic solvent is toluene. ene, or the chiral base is (R)-1-phenyl-2-methyl-propylamine (formula 2B), the organic solvent is ethyl acetate, or the chiral base is (R)-1-phenyl- 2-Methyl-propylamine (Formula 2B) and the organic solvent is 1,2-dichloroethane. do.

[0052] In a preferred embodiment of the present invention and / or embodiments thereof, The aryl base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) The solvent is methyl tert-butyl ether, cyclopentyl methyl ether, tetrahydrofuran Fluorocarbon, dioxane, chlorobenzene, toluene, m-xylene, mesitylene, ethylene acetate butyl acetate, triethylamine, trichloromethane, 1,2-dichloroethane and The mixture is selected from the group consisting of:

[0053] In a preferred embodiment of the present invention and / or embodiments thereof, The aryl base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B), The solvents were methyl tert-butyl ether, cyclopentyl methyl ether, and chlorobenzene. toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine , trichloromethane, 1,2-dichloroethane, and mixtures thereof. can be.

[0054] In a preferred embodiment of the present invention and / or embodiments thereof, The aryl base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B), The solvents are chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, and butyl acetate. , triethylamine, trichloromethane, 1,2-dichloroethane and mixtures thereof The compound is selected from the group consisting of:

[0055] In a preferred embodiment of the present invention and / or embodiments thereof, The aryl base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B), The solvents were chlorobenzene, toluene, ethyl acetate, butyl acetate, triethylamine, trichlorobenzene, The solvent is selected from the group consisting of dichloromethane, 1,2-dichloroethane, and mixtures thereof.

[0056] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) Residue X in (2C) is Cl (chloride) or Br (bromide).

[0057] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2C), the residue X is Cl, and the organic solvents are tetrahydrofuran, dioxane, and toluene. ethyl acetate and mixtures thereof.

[0058] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2C), the residue X is Cl and the organic solvent is methyl tert-butyl ether, cyclohexane. methyl ether, dioxane, chlorobenzene, toluene, m-xylene, methionine ethylene, ethyl acetate, butyl acetate, triethylamine, trichloromethane, 1,2-dichloromethane The inorganic filler is selected from the group consisting of ethane, ethane, and mixtures thereof.

[0059] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2C), the residue X is Cl and the organic solvent is methyl tert-butyl ether, cyclohexane. ethyl methyl ether, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate butyl acetate, triethylamine, trichloromethane, 1,2-dichloroethane and The mixture is selected from the group consisting of:

[0060] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2C), the residue X is Cl, and the organic solvents are chlorobenzene, toluene, ethyl acetate, and acetic acid. Butyl acetate, triethylamine, trichloromethane, 1,2-dichloroethane and mixtures thereof.

[0061] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2C), the residue X is Cl, and the organic solvent is toluene, ethyl acetate, or a mixture thereof. The compound is selected from the group consisting of:

[0062] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) The residue R in (2C) is chloride and the organic solvent is tetrahydrofuran; The residue R in formula (2C) is chloride and the organic solvent is dioxane; or the residue R of formula (2C) is chloride and the organic solvent is toluene; and the organic solvent is ethyl acetate.

[0063] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2C), the residue X is Br, and the organic solvents are tetrahydrofuran, dioxane, and toluene. ethyl acetate and mixtures thereof.

[0064] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) The residue R in (2C) is a bromide and the organic solvent is tetrahydrofuran; The residue R in formula (2C) is a bromide and the organic solvent is dioxane; and the organic solvent is toluene; or the residue R of formula (2C) is a bromide and the organic solvent is toluene; The solvent is ethyl acetate.

[0065] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2C), the residue X is Br and the organic solvent is methyl tert-butyl ether, cyclohexane. methyl ether, dioxane, chlorobenzene, toluene, m-xylene, methionine ethylene, ethyl acetate, butyl acetate, triethylamine, trichloromethane, 1,2-dichloromethane The inorganic filler is selected from the group consisting of ethane, ethane, and mixtures thereof.

[0066] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2C), the residue X is Br and the organic solvent is methyl tert-butyl ether, cyclohexane. ethyl methyl ether, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate butyl acetate, triethylamine, trichloromethane, 1,2-dichloroethane and The mixture is selected from the group consisting of:

[0067] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2C), the residue X is Br, and the organic solvents are chlorobenzene, toluene, ethyl acetate, and acetic acid. Butyl acetate, triethylamine, trichloromethane, 1,2-dichloroethane and mixtures thereof.

[0068] In a preferred embodiment of the present invention and / or embodiments thereof, in step (i) In (2C), the residue X is Br, and the organic solvent is toluene, ethyl acetate, or a mixture thereof. The compound is selected from the group consisting of:

[0069] In step (i), (5RS)-4-[5-(3,5-dichlorophenyl)-5-( Trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid , polarity E T (30) In an organic solvent having a molecular weight of 130 to 175 kJ / mol, a compound represented by the formula (2A), (2 B) or (2C) to form a precipitate and a supernatant solution. In a medium, (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl) (S)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, preferably (S )-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-iso isoxazol-3-yl]-2-methyl-benzoic acid, and The compounds in (2C) interact with each other to form a precipitated product and a supernatant solution. That is, (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluorophenyl) oromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, preferably is (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)- 4H-isoxazol-3-yl]-2-methyl-benzoic acid, and the compounds of formula (2A), (2B ) or (2C) may react with each other and precipitate from the reaction mixture, preferably forms a solid product which can be completely precipitated, leaving a supernatant solution. The supernatant solution is preferably A small amount of unreacted (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoro methyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, and preferably Most of the (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl) ethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid.

[0070] (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl) -4H-isoxazol-3-yl]-2-methyl-benzoic acid of formula (2A), (2B) or the reaction with compound (2C) can be carried out at any temperature as long as the solvent is in a liquid state. For example, the reaction can be carried out at a temperature of 4 to 65° C., preferably 10 to 55° C. or 15 to 45°C, preferably 20 to 40°C, more preferably 25 to 35°C, and most preferably can be carried out at a temperature of about 23° C. (also referred to as room temperature).

[0071] In a preferred embodiment of the present invention and / or embodiments thereof, step (i) comprises the steps of: S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H- [Isoxazol-3-yl]-2-methyl-benzoic acid represented by formula (2A), (2B) or The process involves heating the compound (2C) to high temperatures. The high temperatures are from 23°C (room temperature) to The boiling point of the solvent is preferably 30° C. to the boiling point of the organic solvent minus 5° C., more preferably 40° C. to the boiling point of the organic solvent The temperature is the boiling point of the solvent -20°C. It is the temperature of toluol, which has a boiling point of 111°C or When an ene is used as the organic solvent, the reaction in step (i) is preferably carried out at a temperature of 30° C. to 10 This means that the reaction can be carried out at a temperature of 5°C, more preferably 40°C to 95°C. All temperatures shown and referred to as boiling temperatures or boiling points are at normal pressure of 101 kPa. It concerns temperature as measured by pressure.

[0072] Additionally, step (i) preferably includes cooling the reaction mixture of that step. If (i) does not involve heating the reaction mixture to an elevated temperature, the reaction mixture may be heated to a temperature between 0°C and 2 The reaction mixture may be cooled to about 0° C., preferably about 10° C. When the reaction involves heating at 40° C., the reaction mixture is preferably heated to 0° C. to 40° C., preferably at 1 The reaction mixture can be cooled to 0°C to 30°C, particularly to about 23°C (room temperature). Upon cooling, the resulting product forms a precipitate and a supernatant solution, which is preferably , (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)- 4H-Isoxazol-3-yl]-2-methyl-benzoic acid.

[0073] Furthermore, the reaction in step (i) is preferably carried out using mechanical means such as stirring or sonication. You can add movement.

[0074] In a preferred embodiment of the invention and / or embodiments thereof, the duration of step (i) is: It may be 15 minutes to 24 hours, preferably 30 minutes to 12 hours, and particularly 1 hour to 6 hours. Cut.

[0075] In step (ii), the precipitate from step (i) is separated from the supernatant solution. These precipitates are solids and cannot be separated from the supernatant solution by any method that separates solids from liquids. Examples of these methods include isolating the supernatant, optionally with a prior centrifugation step. Decant or pour off the solution and filter.

[0076] In a preferred embodiment of the present invention and / or embodiments thereof, the precipitation from step (i) The separation of the supernatant solution from the liquid is accomplished via filtration. As used herein, filtration refers to the process by which only the liquid is separated from the supernatant solution. Separating a solid, in this case a precipitate, from a liquid, in this case a supernatant solution, through a medium that can pass through Such media may be filters or sieves, preferably An example of a suitable filter is a suction filter. filter, pressure filter or folded filter, preferably a suction filter. .

[0077] In a preferred embodiment of the present invention and / or embodiments thereof, The precipitate from step (i) may be subjected to a further purification step. The preparation step is preferably carried out by, for example, removing the organic solvent from step (i) of the process. This can include washing the precipitate from the supernatant to remove any remaining sticky supernatant. The solution could then be removed.

[0078] In step (ii), the precipitate from step (i) separated from the supernatant solution is preferably further The residual solvent can be removed by drying at a temperature of preferably 23° C. to 50° C. , preferably at a temperature of about 40° C. and / or at a pressure of 1 kPa to 90 kPa; preferably at a pressure of about 10 kPa The operation can be carried out under reduced pressure of 100 Pa.

[0079] In step (iii), the precipitate from step (ii) is treated with an aqueous acid. An aqueous solution is a solution having a pH value of less than 7.

[0080] Furthermore, the acidic aqueous solution is preferably obtained by reacting a Bronsted acid with water. This can be done.

[0081] In a preferred embodiment of the present invention and / or embodiments thereof, in step (iii) The acidic aqueous solution has a pKa of 3.5 or less, preferably a pKa of 3.0 or less, and more preferably It is a solution of an acid with a pKa of 2.5 or less, a pKa of 2.0 or less.

[0082] An example of a suitable acid with a pKa of 3.5 or less is hydrogen chloride (the corresponding acid is hydrochloric acid). , hydrogen bromide, hydrogen iodide, nitric acid, sulfuric acid, sodium or potassium hydrogen sulfate, phosphoric acid, Trichloroacetic acid, fumaric acid, maleic acid, oxalic acid, citric acid, lactic acid, 2-chlorobenzoic acid Acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid and mixtures thereof It is.

[0083] The Bronsted acid can be an organic acid or an inorganic acid.

[0084] Examples of organic acids that can be used as Bronsted acids are fumaric acid, maleic acid, cyclohexyl 1,2-dihydropyridine ... Oxalic acid, citric acid, lactic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid Preferred are methanesulfonic acid, ethanesulfonic acid and mixtures thereof. and p-toluenesulfonic acid, especially methanesulfonic acid and p-toluenesulfonic acid It is.

[0085] An example of an inorganic acid that can be used as a Bronsted acid is hydrogen chloride (the corresponding acid is a salt). ), hydrogen bromide, hydrogen iodide, nitric acid, sulfuric acid, sodium hydrogen sulfate or potassium The compounds are phosphate, phosphoric acid and mixtures thereof.

[0086] In a preferred embodiment of the present invention and / or embodiments thereof, in step (iii) The acidic aqueous solution is an inorganic acid, preferably hydrogen chloride, hydrogen bromide, sulfuric acid, sodium hydrogen sulfate or or potassium, phosphoric acid and mixtures thereof, more preferably hydrogen chloride, sodium hydrogen sulfate ammonium or potassium, phosphoric acid and mixtures thereof, especially hydrogen chloride, potassium hydrogen sulfate or a solution of phosphoric acid, especially potassium hydrogen sulfate.

[0087] In a preferred embodiment of the present invention and / or embodiments thereof, in step (iii) The acidic aqueous solution to be used has a pH of -3 to 3.5, more preferably -2 to 3, and even more preferably - It has a pH value of 1 to 2.5, in particular about 2.

[0088] The step (iii) of treating the precipitate from step (ii) with an aqueous acid solution is preferably carried out under cooling. The reaction can be carried out at a temperature of preferably 5°C to 20°C, more preferably about 10°C.

[0089] Furthermore, the reaction of step (iii) is preferably carried out by stirring or sonication, in particular by stirring or sonication. Any mechanical movement can be performed.

[0090] In a preferred embodiment of the present invention and / or embodiments thereof, the duration of step (iii) The time can be from 5 minutes to 2 hours, preferably from 10 minutes to 1 hour, and particularly about 30 minutes.

[0091] In step (iv), (5S)-4-[5-(3,5-dichlorophenyl)-5-(trimethylsilyl)phenyl]- Fluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, The separation is carried out by separating the solid organic compounds, particularly the solid organic acids, from the acidic aqueous solution of step (iii). The separation may include any known method for separating the acid from the aqueous acid solution. decantation of the above solution, optionally with a prior centrifugation step, according to the method described above for The separation may include separating or pouring off and filtering. The desired compound (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoro (methyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid via extraction It is possible to do so.

[0092] In a preferred embodiment of the present invention and / or in step (iv) thereof, (5S)-4-[5-(3,5-dichlorophenyl)-2-(2,4-dichlorophenyl)-2,5-dihydro-2,6-dichlorophenyl-2,7-dihydro-2,8-dihydro-2,9-triazol-1,1-triazol-1,2-triazol-1,3-triazol-1,4-diazol-1,5-diaminetetraacetate from the acidic aqueous solution from step (iii) -5-(trifluoromethyl)-4-Hisoxazol-3-yl]-2-methyl The separation of benzoic acid is carried out by extraction with organic solvents, which are known to those skilled in the art. be.

[0093] In step (iv), the extraction may preferably be carried out in an aprotic organic solvent. Suitable organic solvents for use in this step (iv) are, for example, toluene, benzene, xylene, Diene, ethyl acetate, hexane, heptane, octane, cyclic and non-cyclic alkyl ethers , chlorobenzene, cyclohexane, methylcyclohexane, dichloromethane, dichloro Ethane, trichloromethane, trichloroethane, tetrachloroethane, dimethoxyethane , diethoxyethane, and combinations thereof. Preferred are ethyl acetate, toluene, and the like. toluene, especially ethyl acetate, dichloromethane and trichloromethane. The other is ethyl acetate.

[0094] The extraction preferably comprises adding an organic solvent to the acidified aqueous solution from step (iii); and separating the phase from the aqueous acid solution by means of an organic solvent. The procedure can be preferably repeated, preferably 2 to 4 times. The organic phases are preferably combined and dried. Dehydration can be performed using sodium sulfate or sulfuric acid. This can be done using a known dehydrating agent such as magnesium. After dehydration, the dehydrating agent is preferably The precipitate can be separated from the organic phase by filtration.

[0095] Further, step (iv) preferably comprises removing the organic solvent from the organic phase, preferably the combined organic phase. The organic solvent is preferably removed from the aqueous phase at a temperature of 23° C. to 50° C., preferably At a temperature of about 40° C. and / or under reduced pressure of 1 kPa to 90 kPa, preferably about 10 kPa. This can be done.

[0096] In a preferred embodiment of the present invention and / or embodiments thereof, 5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H Isoxazol-3-yl]-2-methyl-benzoic acid is at least 75%, preferably At least 80%, more preferably at least 85%, especially at least 90% of the energy It has an enantiomeric excess (ee).

[0097] Enantiomeric excess (ee) is defined as the absolute difference between the mole fractions of each enantiomer, It can be expressed as percent enantiomeric excess and is calculated according to the following equation:

number

[0098] During the ceremony, F R is the mole fraction of the (R)-enantiomer, F S is the mole fraction of the (S)-enantiomer.

[0099] The amounts, and therefore the molar fractions, of the corresponding enantiomers can be determined by methods known in the art, e.g. For example, chiral column chromatography ( NMR spectroscopy via chiral LC or SFC or in the presence of chiral shift reagents In this application, the chiral LC model of the corresponding enantiomer can be obtained. The chiral fraction was determined by chiral LC (system: Agilent Technology Agilent Technologies equipped with Ogies 1200 sampler 1100. Phenomenex column with Lux Amylose-1 chiral phase (5 μm) Column (250 mm × 4.6 mm). Eluent: i-hexane:ethanol 75:25; 12 Isocratic run over 2 min. Flow rate: 1 mL / min. Column oven temperature: 35 °C. 220, 2 (UV detection at 54, 265 and 280 nm.) Another possibility is the use of chiral amines or aryl groups. Conversion of (S)-IOBA with cole to diastereomeric amides or esters, and ee% measurement by LC.

[0100] In a preferred embodiment of the invention and / or embodiments thereof, the method further comprises the steps (iv) Product (5S)-4-[5-(3,5-dichlorophenyl)-5-(trimethylphenyl)- Fluoromethyl-4H-isoxazol-3-yl-2-methyl-benzoic acid Recrystallization or recrystallization involves the proper separation of the desired compound and any impurities. The desired compound is then precipitated (recrystallized) while any impurities are removed. The pure product remains in the solvent.

[0101] The compound to be recrystallized is preferably completely dissolved in a solvent, preferably a solvent at its boiling point. The temperature of the solvent is then lowered until the desired product precipitates. It is further preferred to be able to obtain the desired compound (5S)-4-[5-(3,5- Dichlorophenyl)-5-(trifluoromethyl)-4-H-isoxazol-3-yl The separation of 2-methyl-benzoic acid can be carried out, for example, according to the method described above for step (ii). It can be done.

[0102] Suitable organic solvents for recrystallization are, for example, toluene, benzene, xylene, ethyl acetate, hexane. Cyclic and non-cyclic alkyl ethers, chlorobenzene, cyclohexane, methylsilane, cyclohexane and combinations thereof. Preferred are non-cyclic alkyl ethers. , toluene and ethyl acetate.

[0103] In a preferred embodiment of the present invention and / or the method thereof, (5S)-4 -[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxoxy

[0033] Sazol-3-yl-2-methyl-benzoic acid can further be prepared as a compound according to formula (4): [ka]

[0104] to produce (5S)-4-[5-(3,5-dichlorophenyl)-5-(phenyl)-1,2-dichlorophenyl]-2,4-dichlorophenyl-1,2-diaminetetraacetate according to formula (3): -(trifluoromethyl)-4H-isoxazol-3-yl]-N-[2-oxo- 2-(2,2,2-trifluoroethylamino)ethyl]-2-methyl-benzamide obtain. [ka]

[0105] Preferably, (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoro methyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid and the formula (4) The corresponding amide groups are formed in organic solvents in the presence of coupling agents. The coupling agent is preferably a material that promotes the formation of an ester or an amide. The coupling agent reacts with the carboxy group by forming a reactive intermediate, which This is then further reacted with an alcohol or an amine to give the final product, i.e., an ester or Suitable coupling agents include, for example, N,N'-dicyclohexyl carboxylates, Carbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiiimide The derivative can be EDTA, diethyldiimidazole (EDC) or carbonyldiimidazole (CDI).

[0106] Suitable organic solvents can be, for example, dioxane, tetrahydrofuran and DMF. Cut.

[0107] Or, (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl) 4H-isoxazol-3-yl]-2-methyl-benzoic acid is preferably used as a salt thionyl chloride or oxalyl chloride, preferably thionyl chloride, to give the corresponding The corresponding acid chloride can then be dissolved in a suitable organic solvent, e.g. For example, in dioxane, tetrahydrofuran, chloroform or dichloromethane, Furthermore, the reaction of acid chlorides with amines according to formula (4) can be carried out. The reaction is preferably carried out in the presence of an auxiliary alkaline compound. Suitable alkaline compounds are, for example, For example, pyridine and amines such as triethylamine and diisopropylethylamine, Diisopropylethylamine is preferred.

[0108] A further subject of the present invention is a compound according to the formula (1a) 5-(trifluoromethyl)-4H-isoxazol-3-yl]- 2-Methyl-benzoic acid: [ka]

[0109] (5RS)-4-[5-(3,5-dichlorophenyl)-5-( Trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid: [ka]

[0110] A method for producing the same comprising the steps of: (i) (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoro methyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid of formula (2A), Compound (2B) or (2C): [ka]

[0111] [wherein R is an alkyl group having 1 or 2 carbon atoms], [ka]

[0112] [wherein X is Cl or Br], methyl tert-butyl ether, cyclopentene ethyl methyl ether, tetrahydrofuran, dioxane, chlorobenzene, toluene, m -Xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, trichloromethane The reaction is carried out in an organic solvent selected from the group consisting of 1,2-dichloroethane and 1,2-dichloroethane, and the precipitate and the supernatant solution are forming a (ii) separating the precipitate from step (i) from the supernatant solution; (iii) treating the precipitate from step (ii) with an aqueous acidic solution; and (iv) (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoro methyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid in step (iii from the aqueous acid solution of With the proviso that when R is methyl, the solvent in step (i) is not ethyl acetate. do.

[0113] As far as the preferred embodiment is concerned, the same applies as above.

[0114] A further subject of the present invention is the (5S)-4-[5-(3,5-dichloro) Phenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2- Methyl-benzoic acid: [ka]

[0115] (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trimethylsilyl)phenyl]-2-(2-phenylpropanediol) according to formula (1) Fluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid: [ka]

[0116] A method for producing a compound comprising the steps of: (i) (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoro methyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, , (2B) or (2C): [ka]

[0117] [R is an alkyl group having 1 or 2 carbon atoms.] [ka]

[0118] [X is Cl or Br.] and polarity ET (30) 130-175 kJ / mol reacting in a first organic solvent containing 1,2-dichlorophenyl ether to form a precipitate and a supernatant solution; (ii) separating the precipitate from step (i) from the supernatant solution; (iii) optionally treating the precipitate from step (ii) with an aqueous acid; and (iv) optionally, (5S)-4-[5-(3,5-dichlorophenyl)-5-(trimethylsilyl)phenyl]- Fluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid (iii) separating said compound from the acidic aqueous solution; (v) optionally, reacting the product (5S)-4-[5-(3,5-dichloro) Phenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2- recrystallizing methyl-benzoate; (vi) reacting the supernatant solution with an alkaline compound in a second organic solvent; Has With the proviso that when R is methyl, the solvent in step (i) is not ethyl acetate. do.

[0119] (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)- After precipitation of 4H-isoxazol-3-yl]-2-methyl-benzoic acid (S-IOBA) The supernatant was treated with (R)-4-[5-(3,5-dichlorophenyl)-5-( (trifluoromethyl)-4H-isoxazol-3-yl)-2-methyl-benzoic acid (R-IOBA) and (S)-4-[5-(3,5-dichlorophenyl) )-5-(trifluoromethyl)-4H-isoxazol-3-yl)]-2-methyl -benzoic acid (S-IOBA). [ka]

[0120] In most cases, the supernatant was (R)-4-[5-(3,5-dichlorophenyl)-5-(trimethylsilyl) (trifluoromethyl)-4H-isoxazol-3-yl)]-2-methyl-benzoic acid ( R-IOBA) is abundant.

[0121] In step (vi) of the process according to the invention and / or any embodiment thereof, a mixture comprising (R)-IOBA according to formula (1a) and (S)-IOBA according to formula (1b), In an organic solvent, it is reacted with an alkaline compound. This reaction racemises the mixture and gives the (R)- Racemization is the process of shifting the enantiomeric excess of IOBA to a lower value. This is thought of as shifting the enantiomer value to 0, which is the literal meaning of the racemic mixture. It is not something that can be done.

[0122] The alkaline compound can be an organic or inorganic alkaline compound.

[0123] Examples of organic alkaline compounds are diisopropylethylamine (DIPEA), 1,8- Diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo [4.3.0] Non-5-ene and 2-tert-butylimino-2-diethyl tal) Amino-1,3-dimethylperhydro-1,3,2-diazaphosphorine and It is a mixture of these.

[0124] In a preferred embodiment of the present invention and / or embodiments thereof, The alkaline compound is an inorganic compound.

[0125] Examples of suitable inorganic alkaline compounds are alkali or alkaline earth phosphates, alkali carbonates, Alkali or alkaline earth salts, alkali or alkaline earth hydrogen carbonates, or alkaline earth hydroxides, alkali or alkaline earth oxides, or mixtures thereof It is.

[0126] In a preferred embodiment of the present invention and / or embodiments thereof, in step (vi) Alkaline compounds include lithium oxide, sodium oxide, potassium oxide, cesium oxide, and water. Lithium oxide, sodium hydroxide, potassium hydroxide, cesium hydroxide, calcium hydroxide , barium hydroxide, magnesium oxide, calcium oxide, barium oxide, cesium carbonate and and mixtures thereof. Preferred are sodium hydroxide, Calcium hydroxide, potassium hydroxide, cesium hydroxide, calcium hydroxide, barium hydroxide, barium oxide and mixtures thereof.

[0127] In a preferred embodiment of the present invention and / or embodiments thereof, in step (vi) Alkaline compounds include sodium hydroxide, potassium hydroxide, cesium hydroxide, and their The compound may be selected from the group consisting of a mixture of compounds.

[0128] Further alkaline compounds suitable for use in step (vi) are alkali or alkaline Suitable examples are sodium methanolate, potassium methanolate, , sodium ethanolate, potassium ethanolate, sodium tert-butylate and potassium tert-butylate and mixtures thereof.

[0129] Step (vi) of the process of the present invention is carried out in a second organic solvent.

[0130] Suitable second organic solvents are, for example, water, alcohols such as propanol, tetrahydrofuran, Cyclic ethers such as furan and dioxane, aliphatic esters such as ethyl acetate, benzene and unsubstituted or substituted arenes such as benzene and toluene.

[0131] In a preferred embodiment of the present invention and / or embodiments thereof, the second organic solvent is water. , alcohols having 1 to 5 carbon atoms, tetrahydrofuran, dioxane, toluene ethyl acetate and mixtures thereof, more preferably water, 2 to 5 carbon atoms The alcohol may be selected from the group consisting of alcohols having aryl groups, dioxane, toluene, and mixtures thereof. can be.

[0132] In a preferred embodiment of the present invention and / or embodiments thereof, in step (vi) The second organic solvent is an alcohol having 1 to 5 carbon atoms. Preferably, the organic solvent is a monoalcohol. That is, the organic solvent has only one hydroxyl group. It is more preferred that the organic solvent has only hydroxyl functionality. It has no other functional groups apart from one hydroxyl group. Furthermore, it can be used as a second organic solvent. The alcohols having 1 to 5 carbon atoms used contain only hydrogen, oxygen and carbon atoms. Preferably the alcohol is not further substituted.

[0133] An example of an alcohol having 1 to 5 carbon atoms that can be used as an organic solvent is methanol. , ethanol, 1-propanol, 2-propanol, cyclopropyl alcohol, 1- Butanol, 2-butanol, cyclobutanol, 2-methyl-1-propanol, 2- Methyl-2-propanol, 1-pentanol, 2-pentanol, 3-pentanol, Cyclopentanol, 2-methyl-1-butanol, 3-methyl-1-butanol, 3- Methyl-2-butanol, 2-methyl-2-butanol, 2,2-dimethyl-1-propanol and mixtures thereof.

[0134] In a preferred embodiment of the present invention and / or embodiments thereof, the second organic solvent is ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2 -Methyl-1-propanol, 1-pentanol, 2-pentanol, 3-pentanol and mixtures thereof. More preferably, the second organic solvent is ethanol, 1-propanol, 2-propanol, 1-butanol, 1-pentanol, and mixtures thereof. It is an alcohol having 2 to 5 carbon atoms.

[0135] In a particularly preferred embodiment of the present invention and / or embodiments thereof, in step (vi) The second organic solvent has a polarity ET(30) of 130 to 175 kJ / mol in step (i). Same as the first organic solvent.

[0136] In a particularly preferred embodiment of the present invention and / or embodiments thereof, in step (vi) The second organic solvent is ethanol.

[0137] In a particularly preferred embodiment of the invention and / or in step (vi) In this case, the organic solvent is ethanol and the alkaline compound is sodium hydroxide.

[0138] In a particularly preferred embodiment of the invention and / or in step (vi) In this case, the second organic solvent is ethanol and the alkaline compound is potassium hydroxide.

[0139] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is ethanol and the alkaline compound is cesium hydroxide.

[0140] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is ethanol and the alkaline compound is calcium hydroxide.

[0141] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is ethanol and the alkaline compound is barium hydroxide.

[0142] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is ethanol and the alkaline compound is barium oxide.

[0143] In a particularly preferred embodiment of the present invention and / or embodiments thereof, in step (vi) The second organic solvent is 1-propanol.

[0144] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is 1-propanol and the alkaline compound is sodium hydroxide. be.

[0145] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is 1-propanol and the alkaline compound is potassium hydroxide. do.

[0146] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is 1-propanol and the alkaline compound is cesium hydroxide. do.

[0147] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is 1-propanol and the alkaline compound is calcium hydroxide. be.

[0148] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is 1-propanol and the alkaline compound is barium hydroxide. do.

[0149] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is 1-propanol and the alkaline compound is barium oxide. .

[0150] In a particularly preferred embodiment of the present invention and / or embodiments thereof, in step (vi) The second organic solvent is 2-propanol.

[0151] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is 2-propanol and the alkaline compound is sodium hydroxide. be.

[0152] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is 2-propanol and the alkaline compound is potassium hydroxide. do.

[0153] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is 2-propanol and the alkaline compound is cesium hydroxide. do.

[0154] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is 2-propanol and the alkaline compound is calcium hydroxide. be.

[0155] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is 2-propanol and the alkaline compound is barium hydroxide. do.

[0156] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is 2-propanol and the alkaline compound is barium oxide. .

[0157] In a particularly preferred embodiment and / or embodiment thereof of the present invention, in step (vi) The second organic solvent in this case is toluene.

[0158] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is toluene and the alkaline compound is sodium oxide.

[0159] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is toluene and the alkaline compound is potassium oxide.

[0160] In a particularly preferred embodiment of the invention and / or in step (vi) The second organic solvent is toluene and the alkaline compound is cesium oxide.

[0161] In a preferred embodiment and / or embodiment thereof of the present invention, In the alkaline compounds of the mixture containing (S)-IOBA and (S)-IOBA according to formula (1a) The molar ratio of the amine to the amine is 1:1 to 1:10, more preferably 1:2 to 1:8, particularly preferably 1:3 to 1:1. :6, specifically about 1:4.5.

[0162] In a preferred embodiment of the present invention and / or embodiments thereof, step (vi) is The high temperature is a temperature between 23° C. (room temperature) and the boiling point of the organic solvent. In a preferred embodiment and / or embodiment thereof, step (i) is carried out at the boiling point of the organic solvent. All temperatures given herein and relating to the boiling point or points are taken at 101 kPa. The temperatures are measured at atmospheric pressure.

[0163] Furthermore, the reaction in step (vi) is preferably subjected to mechanical treatment such as stirring or sonication. You can add exercise.

[0164] In a preferred embodiment of the present invention and / or embodiments thereof, the duration of step (vi) is 30 minutes to 48 hours, preferably 2 hours to 36 hours, particularly 4 hours to 24 hours. can be done.

[0165] In a preferred embodiment of the present invention and / or embodiments thereof, step (vi) comprises the steps of: The reaction is carried out in the absence of a phase transfer catalyst. Phase transfer catalysts transfer the reaction from one phase to another phase where the reaction takes place. Phase transfer catalysts can be considered as heterogeneous catalysts. Phase transfer catalysts can be difficult to remove from the reaction mixture and / or the desired product. In many cases, reactions that can be carried out without the use of a phase transfer catalyst would be advantageous.

[0166] The resulting mixture obtained after step (vi) is then subjected to any of the methods according to the invention and and / or can be reused in any of its embodiments in step (i). Thus, (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl) Increasing the yield of 4H-isoxazol-3-yl-2-methyl-benzoic acid Furthermore, step (vi) can be used to produce the undesired product (5R)-4-[5-( 3,5-Dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazole- 3-yl]-2-methyl-benzoic acid can be recycled.

[0167] Although the features of the present invention have been described above in the embodiments of the present application, for the sake of brevity, not all combinations of the features have been described. The combination of features is not a literal description. However, the combination of features above is , are expressly considered to be part of the present invention.

[0168] The present invention will now be further illustrated by the following non-limiting examples. This amount of (S)-IOBA is calculated based on the percentage of (S)-IOBA in the Represents 00%.

[0169] Experimental section I. Reproduction of Prior Art I.1 Example 1 of JP05679102 (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl) -4H-Isoxazol-3-yl]-2-methyl-benzoic acid (2.09 g; 5.0 m The mixture was stirred at 54°C. (L)-(-)-α-phenylethylamine ((S)-1-phenylethylamine; 0.304 g; 2.5 mmol) was added, and precipitation began within a few seconds. The mixture was cooled to 4° C. within 1 hour under stirring. The resulting solid was filtered under reduced pressure. After washing with toluene / ethyl acetate 5:1 (5 mL), (5S)-4-[5- (3,5-Dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazole -3-yl]-2-methyl-benzoic acid and (L)-(-)-α-phenylethylamine 1 The :1 diastereomeric salt was obtained as a white solid.

[0170] Yield: 1.12g.

[0171] Enantiomeric excess (ee): 76% I.2 Example 4 of JP05679102 (5S)-4-[5-(3,5- Dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl ]-2-Methyl-benzoic acid and (L)-(-)-α-phenylethylamine 1:1 dimer The stereoisomeric salt (0.5 g) was added to ethyl acetate (10 mL) and toluene (15 mL). Dilute hydrochloric acid (purified water (3 mL) and 35% hydrochloric acid (0.53 g)) was added to it and mixed. The mixture was warmed to 40° C. for 5 min. The phases were separated and the organic phase was washed with dilute hydrochloric acid (purified water ( The mixture was washed with 35% hydrochloric acid (0.53 g) and then with purified water (3 mL). The organic solvent was then distilled from the organic phase under reduced pressure and the residue was dried in vacuum to give the amorphous material 4-[ 5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazo As a result, 1-methyl-3-yl-2-methyl-benzoic acid was obtained.

[0172] Yield: 0.42g.

[0173] Enantiomeric excess (ee): 77%.

[0174] Conclusion: In Example 1 of JP05679102, (5S)-4-[5-(3,5-dichloro Phenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2- Diastereomeric mixture of methyl-benzoic acid and (L)-(-)-α-phenylethylamine 1:1 Since the enantiomeric excess of the mer salt is just 76%, the one cited in the prior art ( 90%ee) was significantly lower than that obtained in Example 4 of JP05679102 (5S). -4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-iso Enantiomeric excess (80% ee) of oxazol-3-yl-2-methyl-benzoic acid The same applies to.

[0175] As far as the yields obtained in both examples are concerned, they are almost the same as those obtained from the prior art. It is equivalent.

[0176] I.3 Example 2 of WO2014 / 090918 Isoxazolinethiophenecarboxylic acid (IOTA) according to WO2014 / 090918 ) and racemic IOBA in a smaller amount, see WO2014 / 090918 Example 2 was carried out again.

[0177] 2-Butanol (4.631 mL), acetonitrile (18.881 mL) and water (0 A ternary solvent mixture consisting of (5RS)-4-[5-(3,5- Dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl ]-2-Methyl-benzoic acid (2 g, 4.78 mmol) was dissolved under stirring. (+)-1-(4-methylphenyl)ethylamine (0.358 mL, 2.433 mmol) 2-butanol (0.515 mL, 5.63 mmol), acetonitrile (2.1 (10 mL, 40.6 mmol) and water (0.110 mL, 6.11 mmol). A solution of the original mixture was prepared and added to the solution of IOBA. The mixture was heated under stirring for 60 The agitator was stopped and the solution was allowed to cool overnight to room temperature. No crystal formation was observed.

[0178] The solvent was evaporated and the residue was dried in vacuum. The material was suspended in acetonitrile (20 mL). The mixture was then heated to 70°C. 2-butanol (4 mL) and water (3.4 mL) were added successively. During this time the reaction mixture was heated to 70° C. After all the water was added a clear solution was obtained. The mixture was cooled and allowed to stand for 2 days.

[0179] A bed of solid material formed. The solid was suspended in the supernatant under stirring to allow further material to settle. After the precipitation of solids stopped, the material was collected and washed with acetonitrile / water 9:1. The solid was dried in vacuum overnight, weighing 610 mg.

[0180] After acidic workup with potassium hydrogen sulfate and extraction with ethyl acetate, the supernatant and solid samples were The samples were analyzed by chiral LC. Chiral LC analysis revealed equal amounts of 1,2-dichlorophenyl ether in both samples. It was revealed that there exist (S)-IOBA and (R)-IOBA.

[0181] Conditions applied in WO2014 / 090918 for the separation of IOTA enantiomers is not useful in the case of IOBA for the production of (S)-IOBA.

[0182] II. Screening example according to the present invention (smaller scale) II.1 (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoro A general synthesis of 4-methyl-4-isoxazol-3-yl-2-methylbenzoic acid. order Stage (i) (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl) -4H-isoxazol-3-yl]-2-methyl-benzoic acid (92 mg) Prepare solutions in solvents A through M (1.1 mL). Stir the mixture and, if necessary, wait until the solid has dissolved. Equal amounts of the solution (500 μL) were added to 13×2 vials (13 rows, 2 columns). L) Reaction block containing A–M; one solution per row. The corresponding neat chiral base 1 and 2 (0.6 equiv.) was added (1 base / row) and the mixture was heated to 75° C. for 10 min. The reaction mixture was then cooled to room temperature under stirring.

[0183] Stage (ii) Separating the supernatant solution from the reaction mixture of step (i) containing the precipitate by filtration or centrifugation. The recovered colorless solid was washed with a corresponding solvent, and the suspension was filtered or centrifuged again. The resulting solid was dried overnight.

[0184] Stage (iii) The dry solid material was suspended in ethyl acetate and the resulting suspension was diluted with water and potassium hydrogen sulfate. The aqueous phase had a pH of about 1. The two phases were mixed until all solid material was dissolved. did.

[0185] Stage (iv) The organic (ethyl acetate) phase of the biphasic system was separated. The aqueous phase of the biphasic system was extracted twice with ethyl acetate. The organic phases were combined and the solvent was evaporated to give a colorless material.

[0186] The obtained (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl) [4H-isoxazol-3-yl]-2-methyl-benzoic acid is the enantiomeric form It has a thiomeric excess. [Table 1]

[0187] As can be seen from the table, the obtained (5S)-4-[5-(3,5-dichlorophenyl)-5 -(Trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid The acid is, particularly when (R)-1-phenyl-propylamine is used as the chiral base, Advantageous enantiomeric excess or significantly higher enantiomeric excess than in the prior art (JP05679102) This indicates thiomeric excess.

[0188] III. Working example (larger scale) III.1 In a flask equipped with a condenser and a thermometer, add 2-propanol (12.5 mL) and water. (0.85 mL) was added. Solid potassium hydroxide (0.671 g, 11.96 mmol) Dissolve in a solvent and obtain (5R)-4-(5-(3,5-dichlorophenyl) -5-(trifluoromethyl)-4H-isoxazol-3-yl)-2-methylbenzo Fragrance acid (1 g, 2.391 mmol) was added at 23° C. (room temperature). The mixture was heated to 80° C. It was decided.

[0189] To determine the degree of racemization, 50 μL samples were taken at 1 hour, 2 hours, and 16 hours, respectively. Each sample was treated as follows: it was diluted with KHSO4 solution (1 The reaction was quenched with 2 mL of ethyl acetate (2.3 M) and extracted twice with ethyl acetate (1 mL and 1 mL). The combined organic phases were concentrated under reduced pressure. The residue was dried under oil pump vacuum and Dissolved in a 1:1 mixture of i-hexane:ethanol (1 mL).

[0190] The obtained (R)-IOBA was 84.8% after 1 hour, 84.5% after 2 hours, and 16:00 After a short time, it has an enantiomeric excess of 64%.

[0191] III.2 Put 2-propanol (6.67 mL) into a flask equipped with a condenser and a thermometer. , 86.4% ee of (5R)-4-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)phenyl (fluoromethyl)-4H-isoxazol-3-yl)-2-methylbenzoic acid (1g, 2 Sodium hydroxide (0.393 g, 9.83 mmol) was dissolved in the solution. Micropearl was added at 40° C. and the mixture was heated to reflux to give a yellow suspension.

[0192] To determine the degree of racemization, 50 μL samples were taken at 2 hours, 4 hours, and 20 hours, respectively. Each sample was treated according to the method described in Example 1.

[0193] The obtained (R)-IOBA was 62.4% after 2 hours, 35.0% after 4 hours, and 20.0 hours. After a short time, it has an enantiomeric excess of 31.8%.

[0194] III.3 >99% ee of (5R)-4-(5-(3,5-dichlorophenyl)propanediol in a 1 mL conical vial (phenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl)-2-methyl Dissolve diethylbenzoic acid (50 mg, 0.120 mmol) in 2-propanol (299 μL). The liquid was a solution of potassium hydroxide in 2-propanol (20.38 μL, 0.359 mmol). The mixture was heated to 90° C. overnight.

[0195] A 100 μL sample of the reaction mixture was concentrated to a solid and dissolved in KHSO4 (15%) in water. The mixture was diluted with 1 mL of ethyl acetate and extracted with 1-2 mL of ethyl acetate. The organic phase was separated and concentrated. The solution was dried under reduced pressure and dissolved in i-hexane:ethanol 1:1 (1 mL). Then, 250 μL was diluted with i-hexane:ethanol 1:1 (1 mL) and the chiral LC-D The (R)-IOBA obtained was analyzed by AD. The enantiomeric excess was 56.47%. had a surplus.

[0196] III.4 >99% ee of (R)-4-(5-(3,5-dichlorophenyl)acetamide in a 1 mL conical vial nyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl) -2-Methylbenzoic acid (50 mg, 0.120 mmol) in 2-propanol (299 μ A solution of cesium hydroxide in 2-propanol (66.8 μL, 0.359 mmHg) was The mixture was heated to 90° C. overnight.

[0197] A 100 μL sample of the reaction mixture was concentrated to a solid and dissolved in KHSO4 (15%) in water. The mixture was diluted with 1 mL of ethyl acetate and extracted with 1-2 mL of ethyl acetate. The organic phase was separated and concentrated. The solution was dried under reduced pressure and dissolved in i-hexane:ethanol 1:1 (1 mL). Then, 250 μL was diluted with i-hexane:ethanol 1:1 (1 mL) and the chiral LC-D The (R)-IOBA obtained was analyzed by AD. The enantiomeric excess was 27.76%. It has a surplus.

[0198] III.5 The flask was equipped with a condenser and a thermometer. 2-propanol (6.67 ml) was added to the flask. L) and dissolve powdered potassium hydroxide (0.671 g, 11.96 mmol) in the solvent. , 87.2% ee of (5R)-4-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)phenyl) (fluoromethyl)-4H-isoxazol-3-yl)-2-methylbenzoic acid (1g, 2 0.391 mmol) was added at 40° C. The mixture was heated to reflux. A clear orange-red solution was formed. After some time, a yellow solid precipitated. The suspension was further heated to reflux for 2 h. Afterwards, a 50 μL sample of the suspension was worked up according to the method described in Example 5. R)-IOBA had an enantiomeric excess of 0.8%.

[0199] As can be seen from Examples 1 to 5, the excess of (R)-IOBA contained in the obtained product Therefore, the mole fraction of (S)-IOBA is reduced by racemization of the starting mixture. It can be concluded that the higher the ratio, the

[0200] III.6 In a 50 mL three-neck flask, add (5RS)-4-(5-(3,5-dichlorophenyl)-5 -(Trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid Acid (2.323 g, 5.0 mmol) and cyclopentyl methyl ether (12.5 mL The reaction mixture was stirred at 23° C. The resulting yellow solution was diluted with (S)-1-phenyl Dipropan-1-amine (0.363 mL, 2.50 mmol) was added, and a white solid was formed. The suspension was heated with stirring to 80°C within 20 min and then to 80°C for another 20 min. Heating was stopped and the suspension was slowly cooled to 40° C. within 2 hours. The heating bath was removed and the suspension was stirred at room temperature overnight.

[0201] The suspension was filtered (frit no. 4) and the filter cake was diluted with cyclopentyl methyl ether. The mixture was washed twice with ethyl acetate (6 mL) and then dried in vacuum at 60°C.

[0202] The obtained ammonium salt was suspended in ethyl acetate (30 mL) and then dissolved in potassium hydrogen sulfate. The organic phase was separated. The aqueous phase was washed with ethyl acetate (20 mL). ) and the combined organic phase was washed with brine (10 mL) and dried over MgSO4. The drying agent was removed by filtration and the solvent was concentrated under reduced pressure. Finally, the residue was dried under high vacuum to give the enantiomers. (S)-IOBA with an omer excess of 95% was obtained.

[0203] Yield: 0.91g (84%).

Claims

1. (S)-4-[5-(3,5-dichlorophenyl)-5-(trichlorophenyl)-2-(phenyl)-1,2-dichlorophenyl]-2,4-dichlorophenyl]-1,2-dichlorophenyl]-2,4-dichlorophenyl]-2,5 ... Fluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid: 【Chemistry 1】 The (RS)-4-[5-(3,5-dichlorophenyl)-5-(trichlorophenyl)-2-(phenyl)-1,2-dichlorophenyl]-2,4-dichlorophenyl]-2,5 ...5-dichlorophenyl]-2,4-dichlorophenyl]-2,5-dichlorophenyl]-2,5-dichlorophenyl]-2,4-dichlorophenyl]-2,5-dichlorophenyl]-2,5-dichlorophenyl]-2,5-di Trifluoromethyl-4H-isoxazol-3-yl)-2-methyl-benzoic acid: 【Chemistry 2】 A method for producing the same comprising the steps of: (i) (RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl) (ethyl)-4H-isoxazol-3-yl)-2-methyl-benzoic acid is reacted with a compound of formula (2A), Compound (2B) or (2C): 【Chemistry 3】 [wherein R is an alkyl group having 1 or 2 carbon atoms], 【Chemistry 4】 [In the formula, X is Cl or Br.] and polarity E T (30) Reacting in an organic solvent having a molecular weight of 130 to 175 kJ / mol, and precipitating forming a filtrate and a supernatant solution; (ii) separating the precipitate from step (i) from the supernatant solution; (iii) treating the precipitate from step (ii) with an aqueous acidic solution; and (iv) (S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl) (4H-isoxazol-3-yl)-2-methyl-benzoic acid, i) from the acidic aqueous solution, With the proviso that when R is methyl, the solvent in step (i) is not ethyl acetate.

2. (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl) -4H-isoxazol-3-yl]-2-methyl-benzoic acid in step (i) is 2A), (2B) or (2C) in a molar ratio of 1:0.4 to 1:

5. The method according to claim 1 .

3. In step (i), the solvent is methyl tert-butyl ether, cyclopentyl methyl ether, Diethyl ether, tetrahydrofuran, dioxane, chlorobenzene, toluene, m-xylene ethylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, trichloromethane, 3. The process according to claim 1 or 2, wherein the aryl group is selected from the group consisting of 2-dichloroethane, 2-dichloroethane and mixtures thereof. 。

4. In step (i), R in formula (2A) is methyl and the solvent is methyl tert-butyl ether. or R in formula (2A) is methyl and the solvent is cyclopentyl methyl ether. or R in formula (2A) is methyl and the solvent is tetrahydrofuran. or R of formula (2A) is methyl and the solvent is dioxane; or 2A) R is methyl and the solvent is chlorobenzene, or or R in formula (2A) is methyl and the solvent is toluene. is m-xylene, or R in formula (2A) is methyl and the solvent is mesitylene. or R of formula (2A) is methyl and the solvent is butyl acetate; is methyl and the solvent is triethylamine, or R in formula (2A) is methyl wherein the solvent is trichloromethane, or R in formula (2A) is methyl, and the solvent is The method according to any one of claims 1 to 3, wherein is 1,2-dichloroethane.

5. In step (i), R in formula (2A) is ethyl and the solvent is methyl tert-butyl ether. or R in formula (2A) is ethyl and the solvent is cyclopentyl methyl ether. or R in formula (2A) is ethyl and the solvent is tetrahydrofuran. R of formula (2A) is ethyl and the solvent is dioxane; or R in formula (2A) is ethyl and the solvent is chlorobenzene; R in formula (2B) is ethyl; wherein the solvent is toluene, or wherein R in formula (2A) is ethyl and the solvent is m-chlorophenyl. or R in formula (2A) is ethyl and the solvent is mesitylene; or R in formula (2A) is ethyl and the solvent is ethyl acetate, or R in formula (2A) is ethyl acetate. R in formula (2A) is ethyl and the solvent is butyl acetate. or R in formula (2A) is ethyl and the solvent is trichloromethane. or R in formula (2A) is ethyl and the solvent is 1,2-dichloroethane. The method according to any one of claims 1 to 4,

6. In step (i), the compound is a compound of formula (2B) and the solvent is tetrahydrofuran. the compound is a compound of formula (2B) and the solvent is dioxane the compound of formula (2B) and the solvent is toluene; or the compound of formula (2B) and the solvent is ethyl acetate; or the compound of formula (2B) or the solvent is 1,2- The method according to any one of claims 1 to 3, wherein the solvent is dichloroethane.

7. In step (i), X in formula (2C) is Br and the solvent is tetrahydrofuran. X in formula (2C) is Br and the solvent is dioxane; or X in formula (2C) is is Cl and the solvent is toluene; or X in formula (2C) is Br and the solvent is The method according to any one of claims 1 to 3, wherein is ethyl acetate.

8. Step (i) comprises reacting a compound of formula (2A), (2B) or (2C) with (R S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H- isoxazol-3-yl)-2-methyl-benzoic acid to high temperatures. The method according to any one of claims 1 to 7.

9. In step (ii), the precipitate from step (i) is separated from the supernatant solution by filtration. The method according to any one of claims 1 to 8, wherein

10. 10. The method according to claim 1, wherein in step (iii), the aqueous acidic solution is an aqueous solution of an inorganic acid.

2. The method according to any one of the preceding claims.

11. In step (iv), (S)-4-[5-(3,5-dichlorophenyl)-5-(trimethylsilyl)phenyl]-2,4-dichlorophenyl]-2,5-diphenyl-2,6-dichlorophenyl]-2,7-diphenyl-2,7-dichlorophenyl]-2,8-diphenyl-2,9-dichlorophenyl]-2,5 ... (trifluoromethyl)-4H-isoxazol-3-yl)-2-methyl-benzoic acid 2. The method of claim 1, wherein the separation from the acidic aqueous solution in step (iii) is carried out by extraction with an organic solvent. The method according to any one of claims 1 to 10.

12. In step (iv), (S)-4-[5-(3,5-dichlorophenyl)-5-(trimethylphenyl)- fluoromethyl-4H-isoxazol-3-yl)-2-methyl-benzoic acid 12. Any one of claims 1 to 11 having an enantiomeric excess (ee) of at least 75%. The method described above.

13. The method further comprises the step of: Recrystallization of (fluoromethyl)-4H-isoxazol-3-yl)-2-methyl-benzoic acid The method of any one of claims 1 to 12, comprising a step (v) of crystallizing.

14. A further step (v) of reacting said supernatant solution with an alkaline compound in a second organic solvent. i), preferably said second organic solvent has a polarity E T (30) 130 to 1 The organic solvent according to any one of claims 1 to 13, which has a molecular weight of 75 kJ / mol. How to.

15. (S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4 H-isoxazol-3-yl)-2-methyl-benzoic acid is further converted into Compound: 【Chemistry 5】 to produce 4-[(5S)-5-(3,5-dichlorophenyl)-4-(phenyl)-2-(2-chlorophenyl)-1,2-dihydro-1,3-dimethylphenyl]-2-(2-methylphenyl)-1,2-dihydro-1,3-dimethylphenyl] ... ,5-dihydro-5-trifluoromethyl-1,2-oxazol-3-yl]-N-[ 2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-o-toluamide : 【Chemistry 6】 The method according to any one of claims 1 to 14, wherein

Citation Information

Patent Citations

  • JP05679102

  • Process for the enantiomeric enrichment of diaryloxazoline derivatives

    WO2014090918A1